title: Response to: 'Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal'.
authors: Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, U.S.A. rosen.karin@gene.com.
authors: K
authors: K
authors: Rosén
authors: M
authors: M
authors: Maurer
authors: H
authors: H
authors: Hsieh
authors: S
authors: S
authors: Saini
authors: C
authors: C
authors: Grattan
authors: A
authors: A
authors: Gimenéz-Arnau
authors: S
authors: S
authors: Agarwal
authors: R
authors: R
authors: Doyle
authors: J
authors: J
authors: Canvin
authors: A
authors: A
authors: Kaplan
authors: T
authors: T
authors: Casale
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011537:Pruritus / Q000188:drug therapy*; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized